drugset / Trial / NCT04979052
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
Phase 2
Completed
65 enrolled
Radboud University Medical Center
Horizon 2020 - European Commission · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Timeline
- Start
- 2022-03-31
- Primary completion
- 2026-03-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interferon gamma-1b | Protein / enzyme biologic | 100 ug | Subcutaneous |